Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Advanced Solid Tumors 2

Interventions

pembrolizumab 3Carboplatin 3Nivolumab 2Injections 2Docetaxel 2Cisplatin 2BMS-753493 2zimberelimab 1urelumab 1tislelizumab 1tesetaxel 1spartalizumab 1olaparib 1liposomal doxorubicin 1linifanib 1lenvatinib 1ixabepilone 1durvalumab 1avelumab 1avdoralimab 1adavosertib 1TAS-119 1Rifampin 1N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 1Maximum Tolerated Dose 1Linoleic Acids, Conjugated 1Lapatinib 1Itraconazole 1Irinotecan 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Advanced Solid Tumors × BMS-753493 × Clear all
NCT00546247 2015-10-12

A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)

Bristol-Myers Squibb

Phase 1/2 Terminated
26 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT00550017 2015-10-12

A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)

Bristol-Myers Squibb

Phase 1/2 Terminated
39 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡